{"preliminary_commentary":{"by_channel":{"x_thread":106,"youtube":22,"podcast":10,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03137771\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-29T03:01:50.076Z","note":"Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.","passages_read":null,"text":"The commentary discusses NRG-LU002’s evaluation of local consolidative therapy, including radiation or surgery, alongside maintenance systemic therapy for oligometastatic NSCLC, compared with maintenance therapy alone. Discussion covers the trial population and its heterogeneity, definitions and biology of oligometastatic disease, and how patterns of spread may affect interpretation. Speakers raise questions about whether radiation to local nodes influences immunotherapy response, how the role of local therapy may change as systemic treatments improve, and which patients may be appropriate for treatment. Translational ctDNA analyses are discussed."},"name":"LU002","nct_id":"NCT03137771","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lu002-nct03137771. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients may receive docetaxel IV over 60 minutes on day 1, erlotinib hydrochloride by mouth daily, or gemcitabine IV over 30 minutes on days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on day 1 alone or in combination with pembrolizumab IV over 30 minutes. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"Arm 1 (systemic maintenance chemotherapy)","type":"ACTIVE_COMPARATOR"},{"description":"Patients undergo local consolidative therapy (LCT) over 2-5 weeks, consisting of SBRT/hypofractionated radiation to the primary tumor and metastatic sites or surgery of metastatic sites. Hypofractionated radiation using IMRT or 3D-CRT can be given in place of SBRT. Within 2 weeks after completion of LCT (3 weeks if surgery occurred), patients receive chemotherapy as in Arm 1.","label":"Arm 2 (LCT + systemic maintenance chemotherapy)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Recurrent Non-Small Cell Lung Carcinoma","Stage IV Non-Small Cell Lung Cancer"],"enrollment":{"count":218,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"3-Dimensional Conformal Radiation Therapy (3D-CRT)","otherNames":["3-dimensional conformal radiation therapy","3-dimensional radiation therapy","3D CONFORMAL RADIATION THERAPY","3D CRT","3D-CRT","Conformal Therapy","Radiation Conformal Therapy"],"type":"RADIATION"},{"name":"Docetaxel","otherNames":["Docecad","RP56976","Taxotere","Taxotere Injection Concentrate"],"type":"DRUG"},{"name":"Gemcitabine","otherNames":["dFdC","dFdCyd","Difluorodeoxycytidine"],"type":"DRUG"},{"name":"Intensity-Modulated Radiation Therapy (IMRT)","otherNames":["IMRT","Intensity Modulated RT","INTENSITY-MODULATED RADIATION THERAPY","Intensity-Modulated Radiotherapy"],"type":"RADIATION"},{"name":"Pemetrexed Disodium","otherNames":["Alimta","LY231514","N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt"],"type":"DRUG"},{"name":"Stereotactic Body Radiation Therapy (SBRT)","otherNames":["SBRT","stereotactic body radiation therapy"],"type":"RADIATION"},{"name":"Erlotinib Hydrochloride","otherNames":["Tarceva"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"}],"last_update":"2026-06-08","lead_sponsor":"NRG Oncology","official_title":"Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2023-12-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"[Phase II] Progression-free Survival","timeFrame":"From randomization to first date of local or regional disease, distant metastases, second primary tumor, death, or last follow-up, whichever comes first. Maximum follow-up time at time of analysis was 5.4 years."},{"measure":"[Phase III] Overall Survival","timeFrame":"From randomization to death or last follow-up."}],"references":[{"citation":"Mattes MD, Eubank TD, Almubarak M, Wen S, Marano GD, Jacobson GM, Ma PC. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer. Clin Lung Cancer. 2021 Jul;22(4):268-273. doi: 10.1016/j.cllc.2021.01.012. Epub 2021 Jan 25.","pmid":"33608212","type":"DERIVED"}],"start_date":{"date":"2017-04-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03137771"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lu002-nct03137771"}